PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma

被引:9
|
作者
Garige, Mamatha [1 ]
Ghosh, Susmita [1 ]
Norris, Alexis [2 ]
Li, Guangyuan [1 ]
Poncet, Sarah [1 ]
Chou, Chao-Kai [3 ]
Wu, Wells W. [3 ]
Shen, Rong-Fong [3 ]
Sourbier, Carole [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Biotechnol Review & Res 1, Off Biotechnol Prod,Off Pharmaceut Qual, Silver Spring, MD 20993 USA
[2] US FDA, Ctr Vet Med, Div Anim Bioengn & Cellular Therapies, Off New Anim Drug Evaluat, Rockville, MD USA
[3] US FDA, Ctr Biol Evaluat & Res, Facil Biotechnol Resources, Drug Adm, Silver Spring, MD USA
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
PD-L1 (B7-H1; CD274); clear cell renal cell carcinoma (ccRCC); interferon gamma; metabolism; tryptophan; kynurenine; glycolysis; INDOLEAMINE 2,3-DIOXYGENASE; SUPPRESSOR-CELLS; INTERFERON-GAMMA; T-CELLS; CANCER; MICROENVIRONMENT; INFLAMMATION; EXPRESSION; LINDAU; ACID;
D O I
10.3389/fonc.2022.858379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immune checkpoint programmed death-ligand 1 (PD-L1) is expressed on the cell surface of tumor cells and is key for maintaining an immunosuppressive microenvironment through its interaction with the programmed death 1 (PD-1). Clear cell renal cell carcinoma (ccRCC) is a highly immunogenic cancer characterized by an aberrant aerobic glycolytic metabolism and is known to overexpress PD-L1. Multiple immunotherapies have been approved for the treatment of ccRCC, including cytokines and immune checkpoint inhibitors. Recently the intrinsic role of PD-L1 and interferon gamma (IFN gamma) signaling have been studied in several types of tumor cells, yet it remains unclear how they affect the metabolism and signaling pathways of ccRCC. Using metabolomics, metabolic assays and RNAseq, we showed that IFN gamma enhanced aerobic glycolysis and tryptophan metabolism in ccRCC cells in vitro and induced the transcriptional expression of signaling pathways related to inflammation, cell proliferation and cellular energetics. These metabolic and transcriptional effects were partially reversed following transient PD-L1 silencing. Aerobic glycolysis, as well as signaling pathways related to inflammation, were not induced by IFN gamma when PD-L1 was silenced, however, tryptophan metabolism and activation of Jak2 and STAT1 were maintained. Our data demonstrate that PD-L1 expression is required to mediate some of IFN gamma's effect in ccRCC cells and highlight the importance of PD-L1 signaling in regulating the metabolism of ccRCC cells in response to inflammatory signals.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
    Abbas, Mahmoud
    Steffens, Sandra
    Bellut, Maria
    Becker, Jan U.
    Grosshennig, Anika
    Eggers, Hendrik
    Wegener, Gerd
    Kuczyk, Markus A.
    Kreipe, Hans H.
    Gruenwald, Viktor
    Schrader, Andres J.
    Ivanyi, Philipp
    MEDICAL ONCOLOGY, 2016, 33 (06)
  • [32] GBP2 promotes clear cell renal cell carcinoma progression through immune infiltration and regulation of PD-L1 expression via STAT1 signaling
    Ye, Shujiang
    Li, Siyu
    Qin, Lei
    Zheng, Wei
    Liu, Bin
    Li, Xiaohui
    Ren, Zhenhua
    Zhao, Huaiming
    Hu, Xudong
    Ye, Nan
    Li, Guangyuan
    ONCOLOGY REPORTS, 2023, 49 (03)
  • [33] Extended Opioid Exposure Modulates the Molecular Metabolism of Clear Cell Renal Cell Carcinoma
    Garige, Mamatha
    Poncet, Sarah
    Norris, Alexis
    Chou, Chao-Kai
    Wu, Wells W. W.
    Shen, Rong-Fong
    Greenberg, Jacob W. W.
    Krane, Louis Spencer
    Sourbier, Carole
    LIFE-BASEL, 2023, 13 (05):
  • [34] MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
    Zou, Jiahuan
    Zhuang, Mengwei
    Yu, Xiaopeng
    Li, Na
    Mao, Rudi
    Wang, Zhida
    Wang, Jianing
    Wang, Xiaoyan
    Zhou, Huaiyu
    Zhang, Lining
    Shi, Yongyu
    MOLECULAR IMMUNOLOGY, 2018, 101 : 203 - 209
  • [35] Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma
    Hsieh, Chih-Cheng
    Hsu, Han-Shui
    Li, Anna Fen-Yau
    Chen, Yann-Jang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : 4433 - 4444
  • [36] Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
    Zhu, Jason
    Armstrong, Andrew J.
    Friedlander, Terence W.
    Kim, Won
    Pal, Sumanta K.
    George, Daniel J.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [37] Clinicopathological correlation and prognostic value of PD-L1 expression in renal cell carcinoma
    Elkhodary, Hoda Sayed
    Nasr, Khaled E.
    Ahmed, Sherif H.
    Shakweer, Marwa M.
    Ezz-Eldin, Mai M. A.
    IMMUNOPATHOLOGIA PERSA, 2022, 8 (02):
  • [38] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [39] PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma
    Zhu, Qian
    Cai, Mu-Yan
    Weng, De-Sheng
    Zhao, Jing-Ding
    Pan, Qiu-Zhong
    Wang, Qi-Jing
    Tang, Yan
    He, Jia
    Li, Min
    Xia, Jian-Chuan
    JOURNAL OF CANCER, 2019, 10 (05): : 1154 - 1161
  • [40] Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens
    Basu, Arnab
    Yearley, Jennifer Holmes
    Annamalai, Lakshmanan
    Pryzbycin, Christopher
    Rini, Brian
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 151 (02) : 217 - 225